Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus N E E 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus N E E 1 35 21.
ENSKYCE vs N.E.E. 1/35 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination estrogen-progestin contraceptive: ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation; increases cervical mucus viscosity to impede sperm penetration; alters endometrial development to reduce implantation likelihood.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally once daily for 21 days, followed by 7 days off.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Norethindrone: terminal half-life 7-8 hours; Ethinyl estradiol: terminal half-life 12-14 hours (with enterohepatic recycling). Clinically, steady state achieved after 5-7 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Norethindrone (NET) and ethinyl estradiol (EE) are excreted primarily in urine (~50-60% as metabolites) and feces (~30-40% as metabolites); less than 1% excreted unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive